(August 25, 2015, 12:57 PM EDT) -- ST. LOUIS — Alleged statements by Medtronic Inc. sales representatives that an off-label use of its Infuse bone graft would be approved in the future is an opinion and not a fraudulent misrepresentation, a Missouri federal judge said Aug. 24 in dismissing the plaintiff’s lawsuit (Kathleen A. Arthur v. Medtronic, Inc., et al., No. 14-52, E.D. Mo., Eastern Div.; 2015 U.S. Dist. LEXIS 111346).
(Arthur opinion available. Document #28-150903-010Z.)
In 2008, Kathleen A. Arthur underwent an anterior cervical discectomy and fusion surgery in which her surgeon...
Infuse Bone Graft Claim Can’t Be Based On Sales Reps’ Prediction Of Approval
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login